Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Tricida, Inc. (TCDA)  
$0.00 0.00 (0.00%) as of 4:30 Tue 6/13


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 50,050,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.00001 - $0.01465
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Tricida is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, Veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract. Veverimer is a non-absorbed, low-swelling, spherical polymer. It is a single, high molecular weight, crosslinked polyamine molecule. Veverimer is designed to specifically bind and remove hydrochloric acid from the GI tract. Acid binding and removal from the GI tract is an approach to treating metabolic acidosis without introducing deleterious counterions or metals.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,822,579
Total Buy Value $0 $0 $0 $40,024,734
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 39
Total Shares Sold 0 0 0 7,293,025
Total Sell Value $0 $0 $0 $13,624,564
Total People Sold 0 0 0 3
Total Sell Transactions 0 0 0 12
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 390
  Page 16 of 16  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Falberg Kathryn E   •       •      –    2018-07-02 4 A $0.00 $0 D/D 3,632 35,211     -
   Falberg Kathryn E   •       •      –    2018-07-02 4 B $19.00 $600,001 D/D 31,579 31,579 0.01     -
   Orbimed Capital Gp V Llc   •       •       •   2018-07-02 4 B $19.00 $6,999,999 I/I 368,421 10,889,280 0.01     -
   Orbimed Capital Gp V Llc   •       •       •   2018-07-02 4 A $0.00 $0 I/I 10,520,859 10,520,859     -
   Bonita David P   •       •       •   2018-07-02 4 A $0.00 $0 D/D 3,632 3,632     -
   Bonita David P   •       •       •   2018-07-02 4 B $19.00 $6,999,999 I/I 368,421 10,889,280 0.01     -
   Bonita David P   •       •       •   2018-07-02 4 A $0.00 $0 I/I 10,520,859 10,520,859     -
   Enright Patrick G   •       •       •   2018-07-02 4 B $19.00 $2,500,001 I/I 131,579 3,019,734 0.01     -
   Enright Patrick G   •       •       •   2018-07-02 4 A $0.00 $0 I/I 2,888,155 2,888,155     -
   Stahl Wilhelm Chief Tech Officer & Sr. VP   •       •      –    2018-07-02 4 B $19.00 $250,002 D/D 13,158 13,158 0.01     -
   Hejlek Edward J SVP, General Counsel & Secy.   •       •      –    2018-07-02 4 B $19.00 $250,002 D/D 13,158 13,158 0.01     -
   Pietzke Steffen VP Fin & Chief Acct Officer   •       •      –    2018-07-02 4 B $19.00 $200,013 D/D 10,527 10,527 0.01     -
   Van Beek Jeroen B Chief Comm Officer and Sr VP   •       •      –    2018-07-02 4 B $19.00 $100,016 D/D 5,264 5,264 0.01     -
   Klaerner Gerrit President and CEO   •       •      –    2018-07-02 4 B $19.00 $300,010 D/D 15,790 705,488 0.01     -
   Parker Geoffrey M. Chief Fin. Officer and Sr. VP   •       •      –    2018-07-02 4 B $19.00 $1,140,000 D/D 60,000 60,000 0.01     -

  390 Records found
  Previous  10  11  12  13  14  15  16    
  Page 16 of 16
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed